A Randomized, Double-Blind, Double-Dummy, Single-Dose, Efficacy Crossover Trial Comparing Formoterol-HFA (pMDI) versus Formoterol-DPI (Aerolizer<sup>TM</sup>) and Placebo (pMDI or Aerolizer<sup>TM</sup>) in Asthmatic Patients

Abstract

The bronchodilatory effect of a 12-microg dose of formoterol inhaled from a CFC-free, HFA-propelled pMDI is significantly superior to placebo and equivalent to a commercially available formoterol DPI.